SEARCH

SEARCH BY CITATION

References

  • 1
    Vazquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health-Syst Pharm 2000; 57: 43748.
  • 2
    Neuhaus P, Klupp J & Langrehr JM. mTORinhibitors: an overview. Liver Transpl 2001; 7: 47384.
  • 3
    Chang GJ, Mahanty HD, Quan D, et al. Experience with the use of sirolimus in liver transplantation – use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000; 6: 73440.
  • 4
    Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992; 257: 973.
  • 5
    Kahan BD. Sirolimus: a new agent for clinical renal transplantation. Transplant Proc 1997; 29: 4850.
  • 6
    Murgia MG, Jordan S & Kahan BD. The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49: 20916.
  • 7
    MadDonald ASfor the Rapamune Global Study Group. A world-wide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 27180.
  • 8
    Trotter JF, Wachs ME, Trouillot TE, et al. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl 2001; 7: 4018.
  • 9
    Watson CJE, Friend PJ, Jamienson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67: 5059.
  • 10
    McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7: 7018.
  • 11
    Trotter JF, Washs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001; 7: 34351.
  • 12
    Brattström C, Wilczek H, Tyden G, Böttiger Y, Säwe J, Groth CG. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. Transplant Proc 1998; 30: 39501.
  • 13
    Meier-Kriesche HU, Kaplan B. Toxicity and efficacy of sirolimus: relationship to whole blood concentrations. Clinical Therapeutics 2000; 22(Suppl. B): B93100.
  • 14
    Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination for renal transplantation. Transplantation 1998; 66: 10406.
  • 15
    Tur MD, Garrigue V, Vela C, et al. Apolipoprotein CIII is upregulated by anticalcineurins and rapamycin: implications in transplantation-induced dyslipidemia. Transplant Proc 2000; 32: 27834.
  • 16
    Hoogeveen RC, Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the metabolism of ApoB100-containing lipoproteins in renal transplant patients. Clin Transpl 2001; 72: 124450.
  • 17
    Wilson JD. Plasma protein: apolipoproteins, receptors, and enzymes. In: WilliamsRH, ed. Textbook of Endocrinology, 9th edn. W.B. Saunders Company, 1998: 1103.
  • 18
    Witzum JL, Steinberg D. The hyperlipoproteinemias. In: CecilR, ed. Textbook of Medicine 2000, 21st edn. W.B. Saunders Company, 1090100.